Zhou Y, Jiang W, Zeng L, Mi J, et al. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. Lung Cancer 2020;143:55-59.
PMID: 32208297